Bavarian Nordic seeks NASDAQ listing

Bavarian Nordic A/S (CSE:BAVA) filed to raise up to $86.3 million through the sale of ADSs on NASDAQ in an offering underwritten by Cowen, Piper Jaffray and Nomura.

This half, the company expects data from a Phase I trial of recombinant vaccine MVA-BN RSV to treat respiratory syncytial virus (RSV). Next half, it plans to start a Phase II trial of CV-301, a vaccine targeting carcinoembryonic antigen (CEA) and mucin 1 ( MUC1; CD227), to treat non-small cell lung cancer (NSCLC). ...